Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
November 22 2019 - 8:00AM
Business Wire
Horizon Therapeutics plc (Nasdaq: HZNP) announced today the
opening of its new office in South San Francisco, located at 2
Tower Place, 12th floor. The 20,000 square-foot facility will
feature laboratory space that will enable formulation and process
development for manufacturing, as well as bioanalytical method
development and other R&D functions.
“This is a significant step as we continue to grow our
manufacturing and R&D capability to address patient needs
through the development of groundbreaking therapies,” said Timothy
Walbert, chairman, president and chief executive officer, Horizon.
“We are excited to join the thriving life sciences community of
South San Francisco, allowing us the opportunity to connect to
newer technologies, leading academic institutions and the dynamic
scientific area at large.”
“This new facility will allow us to function more seamlessly and
efficiently as we expand our pipeline,” said Srini Ramanathan
Ph.D., vice president, development sciences and site head for the
South San Francisco, Horizon. “We look forward to exploring new
partnerships in the South San Francisco biotech hub, and tapping
into the wealth of talent in the area’s biotech and academic
communities, as we develop new solutions to address needs in rare
diseases and beyond.”
Horizon plans to add new positions in bioanalysis, clinical
research, pharmacology, manufacturing and business development
during the next year.
“Horizon brings nearly a decade of rare disease expertise to the
Bay Area,” said Mike Guerra, president and chief executive officer
of the California Life Sciences Association. “We welcome their
addition to the over 3,400 life sciences companies in California,
and eagerly await their contributions to California and the
industry.”
About Horizon Therapeutics plc
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com, follow us @HorizonNews on
Twitter, like us on Facebook or explore career opportunities on
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to Horizon’s
plans to expand its R&D capabilities, the potential benefits of
its South San Francisco facilities; and business and other
statements that are not historical facts. These forward-looking
statements are based on Horizon’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
that Horizon’s actual future financial and operating results may
differ from its expectations or goals; risks relating to Horizon’s
ability to successfully implement its business strategies; risks
inherent in developing novel medicine candidates; risks in the
ability to recruit, train and retain qualified personnel; and those
risks detailed from time-to-time under the caption "Risk Factors"
and elsewhere in Horizon’s filings and reports with the SEC.
Horizon undertakes no duty or obligation to update any
forward-looking statements contained in this press release as a
result of new information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191122005241/en/
U.S. Media Contact: Geoff Curtis Executive Vice
President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Ireland Media Contact: Gordon MRM Ray Gordon
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Sep 2023 to Sep 2024